Galectin Therapeutics (GALT) Minority Interest (2010 - 2016)
Galectin Therapeutics' quarterly Minority Interest came in at $1.7 million in Q3 2016, down 52.73% quarter-over-quarter from $3.6 million in Q2 2016.
Galectin Therapeutics has reported Minority Interest for 5 years, with the latest figure at $1.7 million in Q3 2016.
- For the quarter ending Q3 2016, Minority Interest changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Sep 2016 stood at $1.7 million (changed N/A YoY), and the FY2015 full-year result was $1.7 million, changed N/A from the prior year.
- Minority Interest for Q3 2016 stood at $1.7 million, down from $3.6 million in the prior quarter.
- The five-year high for Minority Interest was $3.6 million in Q2 2016, with the low at $1.7 million in Q4 2015.
- Average Minority Interest over 3 years is $2.2 million, with a median of $1.7 million recorded in 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 1.72 Mn |
| Jun 30, 2016 | 1.76 Mn |
| Mar 31, 2016 | 1.75 Mn |
| Dec 31, 2015 | 1.75 Mn |
| Mar 31, 2012 | 2.74 Mn |
| Dec 31, 2011 | 2.15 Mn |
| Sep 30, 2011 | 2.63 Mn |
| Jun 30, 2011 | 2.20 Mn |
| Dec 31, 2010 | 1.66 Mn |